Brain tumour clinical trial title

Biomede – Biological Medicine for Diffuse Intrinsic Pontine Glioma (study ID: 33023)

Brain tumour type

Glioma, 

Website

www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-targeted-cancer-therapies-for-children-and-young-people-with-a-brain-tumour-biomede

Description:

Biomede is an international, multicenter, randomised, open-label, adaptive, phase II trial of treatment for Diffuse Intrinsic Pontine Glioma (DIPG). This trial mandates a biopsy of the tumour to obtain the biological profile of the tumour. The allocation of treatment in each patient will be based on the specific biological tumour profile. Recruitment target is 80 patients in the UK, 250 in the EU with DIPG over 4 years. The initial agents to be studied based on biomarkers profile are; Dasatinib, Erlotinib and Everolimus as single agents combined with standard radiotherapy.

Date added: 12th January 2019

Open/Closed: Open

Trial ends: April 2021

Provider

Institute of Cancer Research

Contact details

Diva Jain :
15 Cotswold Road
Sutton
London
SM2 5NG
E-mail: biomede@trials.bham.ac.uk
Telephone:

Find on Google maps »